OTC boost for China Pharma
This article was originally published in The Tan Sheet
Executive Summary
China Pharma Holdings' 2008 net income grows 39 percent to $17.8 million due to a 76.6 percent sales increase of OTC cold and flu product PuSen OK (naproxen and pseudophedrine), the only generic version of Bayer's Aleve-D in China. Located in Haikou, the capital of the Hainan province, China Pharma markets 18 products treating infectious diseases, flu/cold and cardiovascular disease and makes nutritional supplements and traditional Chinese medicine, according to a March 17 release. The company is developing generic drugs for off-patent blockbuster drugs but is shifting to an innovative biopharmaceutical enterprise through the products in its pipeline